Dexamethasone, ifosfamide, carboplatin, and etoposide in treating patients with refractory lymphoblastic lymphoma.
Phase 2
Recruiting
- Conditions
- ymphoblastic lymphoma
- Registration Number
- JPRN-UMIN000016346
- Lead Sponsor
- Japan children's cancer group.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) Down syndrome. 2) Existence of CNS infiltration. 3) Philadelphia chromosome positive disease. 4) Myelodysplastic syndromes. 5) Other previous illness of malignant tumor. 6) Previous therapy of organ transplantation including blood stem cells. 7) Previous illness of congenital and HIV related immunodeficiency. 8) Additional status that a doctor in charge judges to be improper.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method